Neumora Therapeutics Total Liabilities 2023-2024 | NMRA

Neumora Therapeutics total liabilities from 2023 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Neumora Therapeutics Total Liabilities 2023-2024 | NMRA

Neumora Therapeutics total liabilities from 2023 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.9B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$134.2B
Vertex Pharmaceuticals (VRTX)$121.1B
Bristol Myers Squibb (BMY)$111.6B
CSL (CSLLY)$80.7B
GSK (GSK)$75.7B
Regeneron Pharmaceuticals (REGN)$75B
Argenex SE (ARGX)$38.9B
Alnylam Pharmaceuticals (ALNY)$32.4B
BioNTech SE (BNTX)$28.7B
BeiGene (ONC)$23.2B
Biogen (BIIB)$20B
Illumina (ILMN)$16.3B
Insmed (INSM)$15B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.4B
Moderna (MRNA)$13.8B
Intra-Cellular Therapies (ITCI)$13.7B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.5B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Bio-Techne Corp (TECH)$10.4B
Vaxcyte (PCVX)$10.4B
Sarepta Therapeutics (SRPT)$10.2B
Exelixis (EXEL)$9.8B
Ascendis Pharma (ASND)$9.4B
Exact Sciences (EXAS)$9.3B
Bio-Rad Laboratories (BIO.B)$8.7B
QIAGEN (QGEN)$8.7B